Strategic acquisitions and strong organic growth for Medical Solutions

Sales rose, but margins and profits declined despite recent acquisitions.

What the company is saying

Nolato AB presents its third quarter 2026 results as a period of continued sales growth, with group sales reaching SEK 2,500 million, a 3% increase adjusted for currency and acquisitions. The company highlights strong organic growth in its Medical Solutions segment, which saw a 9% adjusted sales increase to SEK 1,469 million, driven by higher volumes in Drug delivery and In vitro diagnostics. Management, led by President and CEO Anders Björklund, frames the narrative around resilience in a challenging environment, attributing margin pressure to higher input costs. The announcement emphasizes successful completion and integration of the Unitron and M&M Qualtech acquisitions, consolidated as of September, and projects their annual contribution at approximately SEK 600 million with EBITA margins in line with the group. Expansion investments at existing facilities are described as proceeding according to plan, though without quantitative milestones. The tone is measured and factual, with explicit acknowledgment of margin compression and profit declines.

What the data suggests

The disclosed figures show group sales for Q3 2026 at SEK 2,500 million, up from SEK 2,342 million, but operating profit (EBITA) fell to SEK 254 million from SEK 281 million, with the EBITA margin dropping to 10.2% from 12.0%. Profit after tax decreased to SEK 172 million from SEK 215 million, and earnings per share declined to SEK 0.64 from SEK 0.80. Cash flow from operating activities improved to SEK 332 million from SEK 301 million. Medical Solutions outperformed, with sales up 9% adjusted to SEK 1,469 million and EBITA rising to SEK 166 million, though its margin also slipped to 11.3% from 12.1%. Engineered Solutions was flat on sales at SEK 1,040 million but saw a 3% adjusted decrease and EBITA margin contraction to 10.8%. For the first nine months, group sales rose to SEK 7,311 million (up 3%), but EBITA, profit after tax, and EPS all declined. The company’s net liabilities to EBITDA ratio is a conservative 1.0x. The only realised impact from acquisitions is a one-month contribution, with the SEK 600 million annual figure remaining a forward-looking estimate. The main driver of margin erosion is higher input prices, as stated by management.

Analysis

The announcement is balanced and factual, with the majority of claims supported by realised, quantitative financial data for both the quarter and year-to-date. While there are some forward-looking statements regarding the expected annual contribution of recent acquisitions and ongoing expansion investments, these are presented alongside concrete, completed actions (acquisitions closed, integration begun). The tone is measured, and there is no evidence of narrative inflation or exaggerated claims; qualitative statements about strategic positioning and future benefits are typical for such updates and do not overstate progress. The financial direction is actually deteriorating, with margins and profits down despite modest sales growth, but this is transparently disclosed. No large capital outlay is paired with only long-dated, uncertain returns; the disclosed investments and acquisitions are already completed and partially reflected in results. The gap between narrative and evidence is minimal, with only minor unsupported qualitative claims.

Risk flags

• ●Margin compression is evident, with the group EBITA margin dropping from 12.0% to 10.2% in Q3 and from 11.5% to 10.4% for the nine months. This signals that rising input costs are outpacing sales growth, which could persist if inflationary pressures continue.
• ●Profit after tax and earnings per share both declined year-on-year, indicating that topline growth is not translating into improved bottom-line performance. This raises concerns about the sustainability of profit growth if cost pressures are not contained.
• ●The projected SEK 600 million annual contribution from recent acquisitions is not yet fully realised in reported results, introducing execution risk around integration and actual financial uplift. If integration challenges or market headwinds arise, the expected benefits may not materialise as forecast.
• ●Segment performance is uneven, with Engineered Solutions showing flat sales and declining margins, and Automotive within this segment experiencing sharp declines. This exposes the group to end-market volatility and concentration risk in underperforming sub-sectors.

Bottom line

Nolato AB delivered modest sales growth in Q3 2026, but profitability weakened as margins and net income declined. The company’s Medical Solutions segment was the main growth engine, while Engineered Solutions lagged, particularly in Automotive. Recent acquisitions are expected to boost annual sales by SEK 600 million, but only a partial impact is reflected so far, and integration risks remain. Management is transparent about the impact of higher input costs on margins, and the company’s balance sheet remains strong with net liabilities at 1.0x EBITDA. Investors should focus on whether margin pressure can be reversed and if the full financial benefits of acquisitions are realised in subsequent quarters. The key takeaway is that while sales momentum continues, profit growth is under threat from cost inflation and uneven segment performance.

Announcement summary

(LSE:0OA9) Nolato AB reported third quarter 2026 sales of SEK 2,500 million, up from SEK 2,342 million in the prior year, representing a 3% increase when adjusted for currency and acquisitions. Operating profit (EBITA) for the quarter was SEK 254 million, compared to SEK 281 million, with an EBITA margin of 10.2% versus 12.0% last year. Profit after tax totaled SEK 172 million, down from SEK 215 million. Earnings per share, basic and diluted, were SEK 0.64, compared to SEK 0.80. Cash flow from operating activities increased to SEK 332 million from SEK 301 million. In the Medical Solutions business area, sales reached SEK 1,469 million (up from SEK 1,311 million), a 9% increase adjusted for currency and acquisitions, with operating profit (EBITA) of SEK 166 million (159) and an EBITA margin of 11.3% (12.1%). Growth in Medical Solutions was driven by increased volumes of newer products in Drug delivery and In vitro diagnostics (IVD). Investments in expansion at existing facilities are proceeding according to plan. The acquisitions of Unitron (Netherlands) and part of Qualtech (Ireland) were completed and included in the quarter on a one-month basis, with most sales in Drug delivery. Engineered Solutions sales were SEK 1,040 million (1,035), a 3% decrease adjusted for currency and acquisitions, with EBITA of SEK 112 million (120) and an EBITA margin of 10.8% (11.6%). Consumer electronics volumes were stable, Automotive declined sharply, and Hygiene saw lower sales but stabilized volumes. The Other market area grew, now including most of the business area’s share of the Qualtech acquisition. Materials saw a sharp increase in volume and robust profitability, with significant shipment volume growth in data centers/satellites, aerospace/defense, and automotive. A one-time item of SEK 8 million for acquisition costs was charged to consolidated profit, while the previous year included a SEK 7 million net insurance claim gain. For the first nine months of 2026, group sales were SEK 7,311 million (7,190), a 3% increase adjusted for currency and acquisitions. Group operating profit (EBITA) was SEK 761 million (829), with an EBITA margin of 10.4% (11.5%). Profit after tax was SEK 522 million (626), and earnings per share were SEK 1.94 (2.32). Cash flow from operating activities for the period was SEK 844 million (752). The acquisitions of Unitron and M&M Qualtech, consolidated as of September, are expected to contribute approximately SEK 600 million annually with an EBITA margin in line with the Group. Net liabilities in relation to operating profit (EBITDA) stood at 1.0x at the end of the third quarter. Anders Björklund, President and CEO, stated that group sales increased by 7% in the third quarter, with organic growth of 3% in a challenging environment, and noted the impact of higher input prices on margins. The company continues to optimize its business portfolio and strengthen its position in electronics-intensive medical technology and advanced manufacturing through recent acquisitions.

Disagree with this article?